Diabetes

CV Outcomes in Diabetes

Risk reduction with antihyperglycaemic therapies

 

Cardiovascular (CV) disease remains the leading cause of morbidity and mortality in patients with type 2 diabetes (T2D).

 

The opportunity for CV disease prevention in patients with T2D has recently expanded with antihyperglycaemic agents demonstrating significant reductions in the risk of major adverse cardiovascular events (MACE). Although the exact mechanisms of CV benefit remain uncertain, they appear to be unrelated to the direct glucose-lowering effects. These agents have triggered a shift beyond glucose control, to a broader strategy of comprehensive CV risk reduction.

 

CV specialists are well-positioned to play a key role in managing patients with T2D, including screening, aggressively treating CV risk factors, and incorporating the use of antihyperglycaemic agents into routine practice.

Close X
Other videos you might like

Section Advisor

Professor Mikhail N Kosiborod

Saint Luke's America Heart Institute, Kansas City, MO, US

The Radcliffe diabetes and CVD risk program is supported by an educational grant from Novo Nordisk.

Recent Videos

Video

ESC 22: The EMMY Trial: Empagliflozin in Pts with Acute MI

Harald Sourij,

Watch time: 2:55

Video

ESC 22: ASCEND: Aspirin and Omega-3 Fatty Acids in Preventing Heart Failure

Michelle Goonasekera,

Watch time: 5:34

Video

View from the Thoraxcenter – What's Hot at ESC 2022

Nicolas M Van Mieghem, Joost Daemen,

Watch time: 24:27

Video Series

e-SPACE CRM 2022

Andrew JS Coats, Stefan Anker,

Video

EMPEROR-Preserved: Empagliflozin, Health Status, & QoL in Patients With HFp

Javed Butler,

Video

ESC 2021 Discussion: The FIGARO-DKD Trial

Bertram Pitt, Harriette Van Spall,